Seasonal Influenza Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis

The Key Seasonal Influenza Companies in the market include - Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Novavax, Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others.

DelveInsight's "Seasonal Influenza Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Seasonal Influenza market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Seasonal Influenza Market Forecast [https://www.delveinsight.com/sample-request/seasonal-influenza-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Seasonal Influenza Market Report:

*
The Seasonal Influenza market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In March 2025, Cidara Therapeutics revealed plans to deliver two presentations on CD388 for influenza at the 38th International Conference on Antiviral Research (ICAR).

*
In February 2025, AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") has announced the launch of a plan to develop Ampligen as a vaccine adjuvant for avian influenza, aligning with its antiviral priority pipeline. AIM has partnered with Amarex Clinical Research ("Amarex"), its Clinical Research Organization (CRO), to handle the application and management of a follow-up Investigational New Drug (IND) submission. This study will explore a potential combination therapy involving AIM's Ampligen and AstraZeneca's FluMist, a nasal spray vaccine designed to prevent seasonal influenza.

*
According to the CDC (2024), the 2023-2024 flu season in the US resulted in approximately 40 million flu cases, 18 million medical visits due to the flu, 470,000 hospitalizations, and 28,000 deaths related to influenza.

*
According to estimates by the World Health Organization (WHO), seasonal influenza viruses are responsible for 3 to 5 million severe illness cases and between 290,000 and 650,000 deaths annually, posing a significant public health challenge.

*
Based on secondary research, seasonal influenza is primarily categorized into two types: A and B. Type A influenza represents about 85% of cases, with Type B influenza comprising the other 15%.

*
In 2024, the US recorded the highest number of medical visits related to seasonal influenza, and this figure is anticipated to increase in the coming years.

*
Key Seasonal Influenza Companies: Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Novavax, Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others

*
Key Seasonal Influenza Therapies: XOFLUZA (baloxavir marboxil), RAPIVAB (peramivir), FLUAD QUADRIVALENT, COVID-influenza combination (CIC) vaccine and Stand-alone influenza vaccine, CD388, mRNA-1010, SAB-176, Quadrivalent influenza vaccine, TIVf, and others

*
The Seasonal Influenza epidemiology based on type-specific cases analyzed that More patients of Influenza type-A were found compared to type-B

*
The Seasonal Influenza market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Seasonal Influenza pipeline products will significantly revolutionize the Seasonal Influenza market dynamics.

Seasonal Influenza Overview

Seasonal influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses that circulate annually, typically during the fall and winter months. It spreads through droplets when an infected person coughs, sneezes, or talks. Symptoms include fever, cough, sore throat, body aches, fatigue, and sometimes complications like pneumonia. Seasonal flu can affect people of all ages and can range from mild to severe. Vaccination is the most effective way to prevent infection and reduce the severity of illness. Annual flu shots are recommended due to the virus's frequent mutations.

Get a Free sample for the Seasonal Influenza Market Report

https://www.delveinsight.com/report-store/seasonal-influenza-market [https://www.delveinsight.com/report-store/seasonal-influenza-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Seasonal Influenza Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Seasonal Influenza Epidemiology Segmentation:

The Seasonal Influenza market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Seasonal Influenza

*
Prevalent Cases of Seasonal Influenza by severity

*
Gender-specific Prevalence of Seasonal Influenza

*
Diagnosed Cases of Episodic and Chronic Seasonal Influenza

Download the report to understand which factors are driving Seasonal Influenza epidemiology trends @ Seasonal Influenza Epidemiology Forecast [https://www.delveinsight.com/sample-request/seasonal-influenza-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Seasonal Influenza Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Seasonal Influenza market or expected to get launched during the study period. The analysis covers Seasonal Influenza market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Seasonal Influenza Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Seasonal Influenza Therapies and Key Companies

*
CD388: Cidara

*
mRNA-1010: Moderna

*
SAB-176: SAB Therapeutics

*
Quadrivalent influenza vaccine: Sinovac Biotech

*
TIV: Novartis

*
XOFLUZA (baloxavir marboxil): Roche and Shionogi

*
RAPIVAB (peramivir): BioCryst Pharmaceuticals

*
FLUAD QUADRIVALENT: Seqirus

*
COVID-influenza combination (CIC) vaccine and Stand-alone influenza vaccine: Novavax

Discover more about therapies set to grab major Seasonal Influenza market share @ Seasonal Influenza Treatment Market [https://www.delveinsight.com/sample-request/seasonal-influenza-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Seasonal Influenza Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Seasonal Influenza Companies: Roche and Shionogi, BioCryst Pharmaceuticals, Seqirus, Novavax, Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others

*
Key Seasonal Influenza Therapies: XOFLUZA (baloxavir marboxil), RAPIVAB (peramivir), FLUAD QUADRIVALENT, COVID-influenza combination (CIC) vaccine and Stand-alone influenza vaccine, CD388, mRNA-1010, SAB-176, Quadrivalent influenza vaccine, TIVf, and others

*
Seasonal Influenza Therapeutic Assessment: Seasonal Influenza current marketed and Seasonal Influenza emerging therapies

*
Seasonal Influenza Market Dynamics: Seasonal Influenza market drivers and Seasonal Influenza market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Seasonal Influenza Unmet Needs, KOL's views, Analyst's views, Seasonal Influenza Market Access and Reimbursement

To know more about Seasonal Influenza companies working in the treatment market, visit @ Seasonal Influenza Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/seasonal-influenza-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Seasonal Influenza Market Report Introduction

2. Executive Summary for Seasonal Influenza

3. SWOT analysis of Seasonal Influenza

4. Seasonal Influenza Patient Share (%) Overview at a Glance

5. Seasonal Influenza Market Overview at a Glance

6. Seasonal Influenza Disease Background and Overview

7. Seasonal Influenza Epidemiology and Patient Population

8. Country-Specific Patient Population of Seasonal Influenza

9. Seasonal Influenza Current Treatment and Medical Practices

10. Seasonal Influenza Unmet Needs

11. Seasonal Influenza Emerging Therapies

12. Seasonal Influenza Market Outlook

13. Country-Wise Seasonal Influenza Market Analysis (2020-2034)

14. Seasonal Influenza Market Access and Reimbursement of Therapies

15. Seasonal Influenza Market Drivers

16. Seasonal Influenza Market Barriers

17. Seasonal Influenza Appendix

18. Seasonal Influenza Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=seasonal-influenza-market-to-reach-new-heights-in-growth-by-2034-delveinsight-predicts-cidara-moderna-sab-therapeutics-sinovac-biotech-novartis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.